Resistant Dermatophytosis: A Stubborn Habit and Major Challenge in Iraq

[1]         G. Lopes, E. Pinto, and L. Salgueiro, "Natural products: an alternative to conventional therapy for dermatophytosis?," Mycopathologia, vol. 182, pp. 143-167, 2017.

[2]         Z. S. Suleri, "Recurrent tinea corporis and cruris: Antifungal resistance or poor compliance?," Journal of Pakistan Association of Dermatologists, vol. 30, pp. 1-2, 2020.

[3]         K. E. Sharquie and R. I. Jabbar, "New multiple therapy of resistant and relapsing dermatophyte infections during epidemic status," Journal of Pakistan Association of Dermatologists, vol. 32, pp. 464-471, 2022.

[4]         K. Sardana, R. Kaur, P. Arora, R. Goyal, and S. Ghunawat, "Is antifungal resistance a cause for treatment failure in dermatophytosis: A study focused on tinea corporis and cruris from a tertiary centre?," Indian Dermatology Online Journal, vol. 9, p. 90, 2018.

[5]         S. Ansari, M. T. Hedayati, K. Zomorodian, K. Pakshir, H. Badali, A. Rafiei, et al., "Molecular characterization and in vitro antifungal susceptibility of 316 clinical isolates of dermatophytes in Iran," Mycopathologia, vol. 181, pp. 89-95, 2016.

[6]         K. E. Sharquie and R. I. Jabbar, "Major Outbreak of dermatophyte infections leading into imitation of different skin diseases: Trichophyton mentagrophytes is the main criminal fungus," Journal of the Turkish Academy of Dermatology, vol. 15, p. 91, 2021.

[7]         T. A. Kubaisi, "Recurrent Dermatophytosis: A Comparative Therapeutic Study using Oral Itraconazole Alone and in combination with Topical Tincture of Iodine," Research Journal of Pharmacy and Technology, vol. 15, pp. 5825-5828, 2022.

[8]         F. Khattab, B. M. Elkholy, M. Taha, A. Abd‐Elbaset, and M. Fawzy, "Voriconazole is superior to combined itraconazole/isotretinoin therapy and itraconazole monotherapy in recalcitrant dermatophytosis," Mycoses, vol. 65, pp. 1194-1201, 2022.

[9]         S. Pathania, S. M. Rudramurthy, T. Narang, U. N. Saikia, and S. Dogra, "A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India," Indian Journal of Dermatology, Venereology and Leprology, vol. 84, p. 678, 2018.

[10]       S. Dogra and T. Narang, "Emerging atypical and unusual presentations of dermatophytosis in India," Clinical Dermatology Review, vol. 1, pp. S12-S18, 2017.

[11]       R. Sacheli and M.-P. Hayette, "Antifungal resistance in dermatophytes: genetic considerations, clinical presentations and alternative therapies," Journal of Fungi, vol. 7, p. 983, 2021.

[12]       A. Fattahi, F. Shirvani, A. Ayatollahi, A. Rezaei‐Matehkolaei, H. Badali, E. Lotfali, et al., "Multidrug‐resistant Trichophyton mentagrophytes genotype VIII in an Iranian family with generalized dermatophytosis: report of four cases and review of literature," International Journal of Dermatology, vol. 60, pp. 686-692, 2021.

[13]       X. Wang, R. Abuliezi, H. Hasimu, L. Zhang, and P. Abliz, "Retrospective Analysis of Tinea Capitis in Xinjiang, China," Mycopathologia, pp. 1-7, 2023.

[14]       M. Durdu, H. Kandemir, A. S. Karakoyun, M. Ilkit, C. Tang, and S. de Hoog, "First Terbinafine-Resistant Trichophyton indotineae Isolates with Phe397Leu and/or Thr414His Mutations in Turkey," Mycopathologia, vol. 188, p. 2, 2023.

[15]       D. Saunte, M. Pereiro‐Ferreirós, C. Rodríguez‐Cerdeira, A. Sergeev, M. Arabatzis, A. Prohić, et al., "Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic," Journal of the European Academy of Dermatology and Venereology, vol. 35, pp. 1582-1586, 2021.